Protocol Ledger

NCT06814145 · Phase II · ACTIVE NOT RECRUITING

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

Interventional Phase II clinical trial protocol NCT06814145 sponsored by Merck & Co. in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-04-16 Enrollment: 440 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06814145
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)440 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06814145
Protocol FieldVerified Registry Value
NCT IdentifierNCT06814145
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment440 participants (ESTIMATED)
Registered Start Date2025-04-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI